NEUROONE MEDICAL TECHNOLOGIES CorpNMTCEarnings & Financial Report
Nasdaq
NMTC Q1 2026 Key Financial Metrics
Revenue
$2.9M
Gross Profit
$1.6M
Operating Profit
$-1.7M
Net Profit
$-1.4M
Gross Margin
54.2%
Operating Margin
-59.0%
Net Margin
-49.7%
YoY Growth
-11.7%
EPS
$-0.03
Financial Flow
NEUROONE MEDICAL TECHNOLOGIES Corp Q1 2026 Financial Summary
NEUROONE MEDICAL TECHNOLOGIES Corp reported revenue of $2.9M for Q1 2026, with a net profit of $-1.4M (-49.7% margin). Cost of goods sold was $1.3M, operating expenses totaled $3.3M.
Key Financial Metrics
| Total Revenue | $2.9M |
|---|---|
| Net Profit | $-1.4M |
| Gross Margin | 54.2% |
| Operating Margin | -59.0% |
| Report Period | Q1 2026 |
NEUROONE MEDICAL TECHNOLOGIES Corp Annual Revenue by Year
NEUROONE MEDICAL TECHNOLOGIES Corp annual revenue history includes year-by-year totals (for example, 2025 revenue was $9.1M).
| Year | Annual Revenue |
|---|---|
| 2025 | $9.1M |
| 2024 | $3.5M |
| 2023 | $2.0M |
| 2022 | $171.2K |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $825776 | $272284 | $3.3M | $1.4M | $1.7M | $2.7M | $2.9M |
| YoY Growth | 195.4% | 31.1% | -63.3% | 234.9% | 0.7% | 105.4% | 906.6% | -11.7% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $5.4M | $4.9M | $5.4M | $6.5M | $4.5M | $10.8M | $10.8M | $8.6M |
| Liabilities | $1.5M | $1.9M | $4.5M | $3.6M | $3.3M | $2.6M | $3.7M | $2.2M |
| Equity | $3.9M | $3.0M | $822013 | $2.9M | $1.1M | $8.2M | $7.1M | $6.4M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-2.2M | $-2.4M | $-2.7M | $208049 | $-56144 | $-1.5M | $-1.5M | $-3.1M |